// App-Quantinova.ai

AB0350 (2022) : ASSESSMENT OF REAL-LIFE PATIENT HANDLING EXPERIENCE OF AVT02 ADMINISTERED SUBCUTANEOUSLY VIA AUTOINJECTOR IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: AN OPEN-LABEL, SINGLE-ARM CLINICAL TRIAL, THEN AN EXTENSION PHASE OF AVT02 ADMINISTERED WITH A PRE-FILLED SYRINGE (ALVOPAD-PEN)

Researchers

Presenter

  • N. Damjanov

Principal Investigators

  • H. Stroissnig

  • M. Steiger

  • J. Sobierska

  • E. Guenzi

  • H. Otto

  • A. Sattar

  • H. N. Haliduola

  • E. Edwald

  • F. Berti

Medical Centers

  • Belgrade University School of Medicine, Department of Rheumatology, Belgrade, Serbia

  • Alvotech Germany GmbH, Clinical and Medical Affairs, Jülich, Germany

  • Alvotech Swiss AG, Clinical and Medical Affairs, Zürich, Switzerland

  • Alvotech UK Ltd, Clinical and Medical Affairs, London, United Kingdom

  • Alvotech hf, Combination Products & Devices, Reykjavik, Iceland

Locations

  • Serbia

  • Germany

  • Switzerland

  • United Kingdom

  • Iceland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • N/A

Study Id's

  • NCT04224194

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved